Life's End Benefits of CannaBidiol and TetrahYdrocannabinol

Inclusion Criteria:

1. Provision of signed and dated informed consent from participant or legallyauthorized representative.

2. Person of any sex/gender 40 years of age or older.

3. Ability to take or be administered liquid medication.

4. Meets DSM-V criteria for Major Neurocognitive Disorder.

5. Current clinically significant agitation as demonstrated by an NPI-agitationsubscale of 4 or above at Screening.

6. Meets at least one of the following requirements:

7. Currently enrolled in out-patient or in-patient hospice care.

8. Stage 6d on the Functional Assessment Staging Test (FAST).

9. Score of 12 or more according to the Advanced Dementia Prognostic Tool (ADEPT)as implemented by the Mitchell Index.

10. Willing to agree not to use cannabinoids in any form (e.g., topically applied,ingested, inhaled, or other form of administration), other than the trialmedication, during the first 12 weeks of the study.

11. Has a third-party clinician (e.g., hospice, palliative care, PCP) who is responsiblefor medical management of the participant outside the study.

12. In the opinion of the investigator, resides in an environment suitable to conduct aclinical trial (i.e., study intervention can be administered and concomitantmedication use can be accurately documented).

13. In the opinion of the site PI, has a study partner (may be paid or unpaid caregiver)able and willing to provide accurate information about the participant, oversee theadministration of study drug, and participate in study visits and informant-basedassessments (usually requires at least 5 hours of contact per week). NOTE: Other knowledgeable informants/informed caregivers may contribute toinformant-based scales; however, the site should identify an informant who will beable to serve as the primary source of information.

14. As assessed by investigator, participant is likely to be able to comply with theprotocol for a minimum of 2 weeks.

Exclusion Criteria:

1. Use of cannabinoids or other forms of marijuana in the 3 weeks prior to Baseline, asbased on self-report.

2. Suspected or known allergic reactions, adverse reactions, or hypersensitivity tocannabinoids and/or components (e.g., () of the study drug (T2:C100 or placebo).

3. Treatment with another investigational drug or other investigational interventionwithin the previous 30 days or five half-lives of the investigational product,whichever is longer.

4. Any condition, which in the opinion of the site PI, Data and Coordinating Center,regulatory sponsor, or Project Lead/Protocol PI, makes the participant unsuitablefor inclusion.